Kenox business model is to develop innovative and improved therapies for unmet medical needs and/or for better patient outcomes. We repurpose approved drugs to inhalation route using innovative formulations, devices/drug delivery systems, and thereby enhancing therapeutic efficacy and/or decreasing adverse effects. A diversified portfolio of NDA - 505(b)(1) and 505(b)(2) products are in different phases of development. Our target indications include Asthma/COPD, Insomnia, Lung cancer/adjuvant therapy, Depression, Chorea, Nicotine replacement therapy, and Pulmonary arterial hypertension.
Please reach out to bd@kenoxpharma.us to learn more about Kenox pipeline and partnering opportunities.
